Published July 5, 2026 Your morning rundown on the Canadian economy, markets, and money moves — TSX hits a record close, CUSMA talks roll past the deadline, the first CGEB payment lands, and what to expect ahead of the Bank of Canada's July 15 decision. 1. TSX closes at a record high on gold-miner strength The S&P/TSX Composite climbed 0.9% to close at a record 35,275 on Friday, July 3, powered by gold mining stocks. Gold prices firmed after U.S. nonfarm payrolls for June came in at roughly half the expected pace, fuelling bets that the Federal Reserve could turn more dovish. Agnico Eagle, Wheaton Precious Metals, and Barrick all posted solid gains, while financials like Scotiabank and BMO also moved higher on easing oil-supply concerns. Why it matters: if you hold Canadian equity index funds in your TFSA or RRSP, resource and financial-sector strength has been doing a lot of the heavy lifting this year — worth knowing if your portfolio feels more concentrated than you'd...
U.S. Drug Tariffs: A Looming Crisis for Global Supply Chains
The U.S. government's decision to impose tariffs on pharmaceutical imports has sent shockwaves through the healthcare industry, raising concerns about potential drug shortages and skyrocketing costs. Industry leaders warn that these tariffs could disrupt critical supply chains, affecting the availability of essential medications and medical devices.
Johnson & Johnson CEO Joaquin Duato has voiced concerns over the impact of these tariffs, advocating for tax incentives instead of trade barriers to support domestic drug manufacturing Warns Tariffs Could Disrupt U.S. Drug Supply Chains](https://www.theglobeandmail.com/investing/markets/stocks/LLY-N/pressreleases/31903548/jj-ceo-jnj-warns-tariffs-could-disrupt-us-drug-supply-chains/). Meanwhile, a recent survey indicates that healthcare executives anticipate significant price hikes, with some predicting an 18% increase in medical equipment costs and a 33% rise in critical device prices.
The American Hospital Association has urged the administration to reconsider these tariffs, emphasizing the reliance of U.S. healthcare providers on international sources for life-saving drugs and supplies. Experts caution that while the tariffs aim to boost domestic production, the transition could take years, leaving patients vulnerable to shortages and inflated prices.
As pharmaceutical companies scramble to adjust their supply chains, the industry faces an uncertain future. Whether these tariffs will achieve their intended goal or exacerbate existing challenges remains to be seen. Policymakers must weigh the long-term consequences carefully to ensure that patient care and affordability are not compromised.
Comments
Post a Comment